Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04632953 · ClinicalTrials.gov registry record
Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
A clinical trial of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), sponsored by Ultragenyx Pharmaceutical.
- Active
- Registry status
- 150
- Enrollment target
- 16
- Study locations
NCT04632953: Active study of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), sponsored by Ultragenyx Pharmaceutical.
NCT04632953 is a study of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) that is active but no longer recruiting, run by Ultragenyx Pharmaceutical. The registered enrollment target is 150 participants. The trial reports 16 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04632953, a study of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), is active but no longer recruiting, sponsored by Ultragenyx Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with LC-FAOD who are enrolled in the DMP.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (16)
Ontario
- CHEO (Children's Hospital Eastern Ontario) - Ottawa
- SickKids (The Hospital for Sick Children) - Toronto
Arizona
- Phoenix Children's Hospital - Phoenix
California
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital of Colorado - Aurora
Florida
- University of South Florida - Tampa
Georgia
- The Emory Clinic - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2035-12 |
What the registry record for NCT04632953 still lists
NCT04632953 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT04632953 lists 16 locations in 15 states (Ontario, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT04632953 about?
NCT04632953 is a clinical study titled "Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program". The primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with LC-FAOD who are enrolled in the DMP.
What is the current status of trial NCT04632953?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2021-11-30. Estimated completion is 2035-12.
What conditions does trial NCT04632953 study?
This clinical trial studies the following conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD).
What interventions are being tested in trial NCT04632953?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04632953?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04632953 being conducted?
This trial has 16 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI